Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

Elisa Lazzari, Phoebe K. Mondala, Nathaniel Delos Santos, Amber C. Miller, Gabriel Pineda, Qingfei Jiang, Heather Leu, Shawn A. Ali, Anusha Preethi Ganesan, Christina N. Wu, Caitlin Costello, Mark Minden, Raffaella Chiaramonte, Alexander Keith Stewart, Leslie A. Crews, Catriona H.M. Jamieson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30-50% of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse.

Original languageEnglish (US)
Article number1922
JournalNature Communications
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

RNA Editing
editing
Multiple Myeloma
regeneration
progressions
Regeneration
adenosines
RNA
Amplification
prognosis
harbors
chromosomes
genes
Inosine
Adenosine Deaminase
therapy
drugs
Chromosomes
Recurrence
Ports and harbors

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Lazzari, E., Mondala, P. K., Santos, N. D., Miller, A. C., Pineda, G., Jiang, Q., ... Jamieson, C. H. M. (2017). Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nature Communications, 8(1), [1922]. https://doi.org/10.1038/s41467-017-01890-w

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. / Lazzari, Elisa; Mondala, Phoebe K.; Santos, Nathaniel Delos; Miller, Amber C.; Pineda, Gabriel; Jiang, Qingfei; Leu, Heather; Ali, Shawn A.; Ganesan, Anusha Preethi; Wu, Christina N.; Costello, Caitlin; Minden, Mark; Chiaramonte, Raffaella; Stewart, Alexander Keith; Crews, Leslie A.; Jamieson, Catriona H.M.

In: Nature Communications, Vol. 8, No. 1, 1922, 01.12.2017.

Research output: Contribution to journalArticle

Lazzari, E, Mondala, PK, Santos, ND, Miller, AC, Pineda, G, Jiang, Q, Leu, H, Ali, SA, Ganesan, AP, Wu, CN, Costello, C, Minden, M, Chiaramonte, R, Stewart, AK, Crews, LA & Jamieson, CHM 2017, 'Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma', Nature Communications, vol. 8, no. 1, 1922. https://doi.org/10.1038/s41467-017-01890-w
Lazzari, Elisa ; Mondala, Phoebe K. ; Santos, Nathaniel Delos ; Miller, Amber C. ; Pineda, Gabriel ; Jiang, Qingfei ; Leu, Heather ; Ali, Shawn A. ; Ganesan, Anusha Preethi ; Wu, Christina N. ; Costello, Caitlin ; Minden, Mark ; Chiaramonte, Raffaella ; Stewart, Alexander Keith ; Crews, Leslie A. ; Jamieson, Catriona H.M. / Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. In: Nature Communications. 2017 ; Vol. 8, No. 1.
@article{3b684991d771401482bfbda5b888895e,
title = "Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma",
abstract = "Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30-50{\%} of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse.",
author = "Elisa Lazzari and Mondala, {Phoebe K.} and Santos, {Nathaniel Delos} and Miller, {Amber C.} and Gabriel Pineda and Qingfei Jiang and Heather Leu and Ali, {Shawn A.} and Ganesan, {Anusha Preethi} and Wu, {Christina N.} and Caitlin Costello and Mark Minden and Raffaella Chiaramonte and Stewart, {Alexander Keith} and Crews, {Leslie A.} and Jamieson, {Catriona H.M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41467-017-01890-w",
language = "English (US)",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

AU - Lazzari, Elisa

AU - Mondala, Phoebe K.

AU - Santos, Nathaniel Delos

AU - Miller, Amber C.

AU - Pineda, Gabriel

AU - Jiang, Qingfei

AU - Leu, Heather

AU - Ali, Shawn A.

AU - Ganesan, Anusha Preethi

AU - Wu, Christina N.

AU - Costello, Caitlin

AU - Minden, Mark

AU - Chiaramonte, Raffaella

AU - Stewart, Alexander Keith

AU - Crews, Leslie A.

AU - Jamieson, Catriona H.M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30-50% of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse.

AB - Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30-50% of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse.

UR - http://www.scopus.com/inward/record.url?scp=85037038486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037038486&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-01890-w

DO - 10.1038/s41467-017-01890-w

M3 - Article

C2 - 29203771

AN - SCOPUS:85037038486

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1922

ER -